Author Topic: (Abst.) Clinical outcomes of patients w/MS treated w/Ocrevus...  (Read 64 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9816
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed (July 27, 2021)--"Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: An observational study":




https://pubmed.ncbi.nlm.nih.gov/34308352/
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9816
  • MS diagnosed 1980
  • Location: Pacific Northwest
An article about this study in Multiple Sclerosis News Today (August 25, 2021)--"Ocrevus reduces MS relapse risk, but linked to more hospitalizations":


https://bit.ly/2WsvVA2



MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
57 Views
Last post August 07, 2020, 02:51:51 pm
by agate
0 Replies
49 Views
Last post August 22, 2020, 05:33:55 pm
by agate
0 Replies
30 Views
Last post September 15, 2020, 09:05:44 pm
by agate
0 Replies
24 Views
Last post November 28, 2021, 08:47:41 pm
by agate
0 Replies
19 Views
Last post April 09, 2022, 07:09:40 am
by agate